Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Linking (Pyr)1apelin-13 pharmacokinetics to efficacy: Stabilization and measurement of a high clearance peptide in rodents.

Onorato JM, Xu C, Chen XQ, Rose AV, Generaux C, Lentz K, Shipkova P, Arthur S, Hennan JK, Haskell R, Myers MC, Lawrence RM, Finlay HJ, Basso M, Bostwick J, Fernando G, Garcia R, Hellings S, Hsu MY, Zhang R, Zhao L, Gargalovic P.

Anal Biochem. 2019 Mar 1;568:41-50. doi: 10.1016/j.ab.2018.12.022. Epub 2018 Dec 31.

PMID:
30605634
2.

Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders.

Liu Q, Shi Q, Marcoux D, Batt DG, Cornelius L, Qin LY, Ruan Z, Neels J, Beaudoin-Bertrand M, Srivastava AS, Li L, Cherney RJ, Gong H, Watterson SH, Weigelt C, Gillooly KM, McIntyre KW, Xie JH, Obermeier MT, Fura A, Sleczka B, Stefanski K, Fancher RM, Padmanabhan S, Rp T, Kundu I, Rajareddy K, Smith R, Hennan JK, Xing D, Fan J, Levesque PC, Ruan Q, Pitt S, Zhang R, Pedicord D, Pan J, Yarde M, Lu H, Lippy J, Goldstine C, Skala S, Rampulla RA, Mathur A, Gupta A, Arunachalam PN, Sack JS, Muckelbauer JK, Cvijic ME, Salter-Cid LM, Bhide RS, Poss MA, Hynes J, Carter PH, Macor JE, Ruepp S, Schieven GL, Tino JA.

J Med Chem. 2017 Jun 22;60(12):5193-5208. doi: 10.1021/acs.jmedchem.7b00618. Epub 2017 Jun 5.

PMID:
28541707
3.

High-throughput screening for Kv1.3 channel blockers using an improved FLIPR-based membrane-potential assay.

Liu K, Samuel M, Tillett J, Hennan JK, Mekonnen B, Soloveva V, Harrison RK, Paslay JW, Larocque J.

J Biomol Screen. 2010 Feb;15(2):185-95. doi: 10.1177/1087057109356209. Epub 2009 Dec 31.

PMID:
20044579
4.

Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogs.

Laurent G, Leong-Poi H, Mangat I, Moe GW, Hu X, So PP, Tarulli E, Ramadeen A, Rossman EI, Hennan JK, Dorian P.

Circ Arrhythm Electrophysiol. 2009 Apr;2(2):171-8. doi: 10.1161/CIRCEP.108.790212. Epub 2009 Feb 13.

PMID:
19808462
5.

GAP-134 ([2S,4R]-1-[2-aminoacetyl]4-benzamidopyrrolidine-2-carboxylic acid) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs.

Hennan JK, Swillo RE, Morgan GA, Rossman EI, Kantrowitz J, Butera J, Petersen JS, Gardell SJ, Vlasuk GP.

J Cardiovasc Pharmacol Ther. 2009 Sep;14(3):207-14. doi: 10.1177/1074248409340779.

PMID:
19721133
6.

Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents.

Piatnitski Chekler EL, Butera JA, Di L, Swillo RE, Morgan GA, Rossman EI, Huselton C, Larsen BD, Hennan JK.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4551-4. doi: 10.1016/j.bmcl.2009.07.014. Epub 2009 Jul 9.

PMID:
19616941
7.

The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model.

Rossman EI, Liu K, Morgan GA, Swillo RE, Krueger JA, Gardell SJ, Butera J, Gruver M, Kantrowitz J, Feldman HS, Petersen JS, Haugan K, Hennan JK.

J Pharmacol Exp Ther. 2009 Jun;329(3):1127-33. doi: 10.1124/jpet.108.150102. Epub 2009 Feb 27.

PMID:
19252062
8.

Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation.

Butera JA, Larsen BD, Hennan JK, Kerns E, Di L, Alimardanov A, Swillo RE, Morgan GA, Liu K, Wang Q, Rossman EI, Unwalla R, McDonald L, Huselton C, Petersen JS.

J Med Chem. 2009 Feb 26;52(4):908-11. doi: 10.1021/jm801558d.

PMID:
19175320
9.

Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis.

Hennan JK, Morgan GA, Swillo RE, Antrilli TM, Mugford C, Vlasuk GP, Gardell SJ, Crandall DL.

J Thromb Haemost. 2008 Sep;6(9):1558-64. doi: 10.1111/j.1538-7836.2008.03063.x. Epub 2008 Jul 4.

10.

Enhancement of ventricular gap-junction coupling by rotigaptide.

Lin X, Zemlin C, Hennan JK, Petersen JS, Veenstra RD.

Cardiovasc Res. 2008 Aug 1;79(3):416-26. doi: 10.1093/cvr/cvn100. Epub 2008 Apr 22.

11.

Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis.

Bedard PW, Clerin V, Sushkova N, Tchernychev B, Antrilli T, Resmini C, Keith JC Jr, Hennan JK, Kaila N, Debernardo S, Janz K, Wang Q, Crandall DL, Schaub RG, Shaw GD, Carter LL.

J Pharmacol Exp Ther. 2008 Feb;324(2):497-506. Epub 2007 Nov 16.

PMID:
18024786
12.

Pharmacological modulation of gap junction function with the novel compound rotigaptide: a promising new principle for prevention of arrhythmias.

Kjølbye AL, Haugan K, Hennan JK, Petersen JS.

Basic Clin Pharmacol Toxicol. 2007 Oct;101(4):215-30. Review.

13.

Increasing gap junctional coupling: a tool for dissecting the role of gap junctions.

Axelsen LN, Haugan K, Stahlhut M, Kjølbye AL, Hennan JK, Holstein-Rathlou NH, Petersen JS, Nielsen MS.

J Membr Biol. 2007 Mar;216(1):23-35. Epub 2007 Jun 14. Review.

PMID:
17568971
14.

Effects of rotigaptide, a gap junction modifier, on defibrillation energy and resuscitation from cardiac arrest in rabbits.

Zhong JQ, Laurent G, So PP, Hu X, Hennan JK, Dorian P.

J Cardiovasc Pharmacol Ther. 2007 Mar;12(1):69-77.

PMID:
17495260
15.

GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats.

Leik CE, Carson NL, Hennan JK, Basso MD, Liu QY, Crandall DL, Nambi P.

Br J Pharmacol. 2007 Jun;151(4):450-6. Epub 2007 Apr 10.

16.

Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs.

Shiroshita-Takeshita A, Sakabe M, Haugan K, Hennan JK, Nattel S.

Circulation. 2007 Jan 23;115(3):310-8. Epub 2007 Jan 15.

PMID:
17224477
17.

Effect of sodium/hydrogen exchange inhibition on myocardial infarct size after coronary artery thrombosis and thrombolysis.

Hennan JK, Driscoll EM, Barrett TD, Fischbach PS, Lucchesi BR.

Pharmacology. 2006;78(1):27-37. Epub 2006 Apr 3.

PMID:
16899991
18.

Identification of ischemia-regulated phosphorylation sites in connexin43: A possible target for the antiarrhythmic peptide analogue rotigaptide (ZP123).

Axelsen LN, Stahlhut M, Mohammed S, Larsen BD, Nielsen MS, Holstein-Rathlou NH, Andersen S, Jensen ON, Hennan JK, Kjølbye AL.

J Mol Cell Cardiol. 2006 Jun;40(6):790-8. Epub 2006 May 5.

PMID:
16678851
19.

The antiarrhythmic peptide rotigaptide (ZP123) increases connexin 43 protein expression in neonatal rat ventricular cardiomyocytes.

Stahlhut M, Petersen JS, Hennan JK, Ramirez MT.

Cell Commun Adhes. 2006 Jan-Apr;13(1-2):21-7.

PMID:
16613777
20.

Rotigaptide (ZP123) reverts established atrial conduction velocity slowing.

Haugan K, Kjølbye AL, Hennan JK, Petersen JS.

Cell Commun Adhes. 2005 Jul-Dec;12(5-6):271-8.

PMID:
16531322
21.

Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis.

Hennan JK, Swillo RE, Morgan GA, Leik CE, Brooks JM, Shaw GD, Schaub RG, Crandall DL, Vlasuk GP.

Thromb Haemost. 2006 Mar;95(3):469-75.

PMID:
16525575
22.

Treatment with the gap junction modifier rotigaptide (ZP123) reduces infarct size in rats with chronic myocardial infarction.

Haugan K, Marcussen N, Kjølbye AL, Nielsen MS, Hennan JK, Petersen JS.

J Cardiovasc Pharmacol. 2006 Feb;47(2):236-42.

PMID:
16495761
23.

Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs.

Hennan JK, Swillo RE, Morgan GA, Keith JC Jr, Schaub RG, Smith RP, Feldman HS, Haugan K, Kantrowitz J, Wang PJ, Abu-Qare A, Butera J, Larsen BD, Crandall DL.

J Pharmacol Exp Ther. 2006 Apr;317(1):236-43. Epub 2005 Dec 12.

PMID:
16344331
24.

The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress.

Haugan K, Olsen KB, Hartvig L, Petersen JS, Holstein-Rathlou NH, Hennan JK, Nielsen MS.

J Cardiovasc Electrophysiol. 2005 May;16(5):537-45.

PMID:
15877626
25.

Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.

Hennan JK, Elokdah H, Leal M, Ji A, Friedrichs GS, Morgan GA, Swillo RE, Antrilli TM, Hreha A, Crandall DL.

J Pharmacol Exp Ther. 2005 Aug;314(2):710-6. Epub 2005 Apr 28.

PMID:
15860572
26.

Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy.

Crandall DL, Elokdah H, Di L, Hennan JK, Gorlatova NV, Lawrence DA.

J Thromb Haemost. 2004 Aug;2(8):1422-8.

27.

Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization.

Elokdah H, Abou-Gharbia M, Hennan JK, McFarlane G, Mugford CP, Krishnamurthy G, Crandall DL.

J Med Chem. 2004 Jul 1;47(14):3491-4.

PMID:
15214776
28.

WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation.

Crandall DL, Hennan JK, Elokdah H, Krishnamurthy G, Antrilli TM, Bauer JS, Morgan GA, Swillo RE.

Biochem Biophys Res Commun. 2003 Nov 28;311(4):904-8.

PMID:
14623266
29.

Prevention of carotid artery thrombosis after oral administration of the glycoprotein IIb/IIIa antagonist CRL42796.

Hennan JK, Willens DE, Driscoll EM Jr, Hong TT, Giboulot T, Lucchesi BR.

J Cardiovasc Pharmacol. 2003 Jul;42(1):71-7.

PMID:
12827029
30.

C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion.

Barrett TD, Hennan JK, Marks RM, Lucchesi BR.

J Pharmacol Exp Ther. 2002 Dec;303(3):1007-13.

PMID:
12438521
31.

Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796.

Hennan JK, Hong TT, Willens DE, Driscoll EM, Giboulot TA, Lucchesi BR.

Br J Pharmacol. 2002 Jul;136(6):927-37.

32.

Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury.

Hennan JK, Hong TT, Shergill AK, Driscoll EM, Cardin AD, Lucchesi BR.

J Pharmacol Exp Ther. 2002 Jun;301(3):1151-6.

PMID:
12023550
33.

Conversion of atrial fibrillation by the experimental antiarrhythmic drug tedisamil in two canine models.

Fischbach PS, Barrett TD, Goyal R, Tran BC, Syed ZA, Hennan JK, Lucchesi BR.

J Cardiovasc Electrophysiol. 2001 Oct;12(10):1138-44.

PMID:
11699522
34.

Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.

Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, Crofford LJ, Lucchesi BR.

Circulation. 2001 Aug 14;104(7):820-5.

PMID:
11502709
35.

Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence.

Barrett TD, Hennan JK, Fischbach PS, O'Neill BP, Driscoll EM Jr, Lucchesi BR.

Br J Pharmacol. 2001 Apr;132(7):1493-500.

36.

Effect of NO donors on protein phosphorylation in intact vascular and nonvascular smooth muscles.

Hennan JK, Diamond J.

Am J Physiol Heart Circ Physiol. 2001 Apr;280(4):H1565-80.

Supplemental Content

Loading ...
Support Center